WellDoc
, a digital health technology leader, today announced a collaboration with LifeScan, Inc., a business within the Johnson & Johnson Diabetes Care Companies to deliver a best-in-class digital health solution for patients living with Type 2 diabetes.
Under the collaboration, WellDoc’s BlueStar product, the first FDA-cleared digital therapeutic for adults who live with Type 2 diabetes, will be integrated with LifeScan’s OneTouch Verio Flex™ Bluetooth® Smart blood glucose monitoring system and OneTouch Reveal® mobile app. The collaboration will seek to leverage LifeScan’s trusted blood glucose monitoring system and mobile application along with the robust data analytics and patient engagement of WellDoc’s clinically validated, reimbursable, mobile prescription therapy, BlueStar®, to create a comprehensive, real-time, personalized approach for the management of Type 2 diabetes.
“Entering into a development agreement with LifeScan, as well as receiving a financial investment from Johnson & Johnson Innovation – JJDC, Inc., marks the start of an important relationship. Together, we will seek to provide those living with Type 2 diabetes a best-in-class diabetes management solution that delivers evidence-based and outcomes-driven support in a consumer-friendly manner,” said Kevin McRaith, CEO of WellDoc. “This is a very significant step forward for our company and has the potential to make a difference in the lives of millions of people living with this chronic disease.”
